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Delaying clinical disease onset would greatly reduce
neurodegenerative disease burden, but the mecha-
nisms influencing early preclinical progression are
poorly understood. Here, we show that in mouse
models of familial motoneuron (MN) disease, SOD1
mutants specifically render vulnerable MNs depen-
dent on endogenous neuroprotection signaling
involving excitability and mammalian target of rapa-
mycin (mTOR). The most vulnerable low-excitability
FF MNs already exhibited evidence of pathology
and endogenous neuroprotection recruitment early
postnatally. Enhancing MN excitability promoted
MN neuroprotection and reversed misfolded SOD1
(misfSOD1) accumulation and MN pathology,
whereas reducing MN excitability augmented mis-
fSOD1 accumulation and accelerated disease. Inhib-
iting metabotropic cholinergic signaling onto MNs
reduced ER stress, but enhanced misfSOD1 accu-
mulation and prevented mTOR activation in alpha-
MNs. Modulating excitability and/or alpha-MN
mTOR activity had comparable effects on the pro-
gression rates of motor dysfunction, denervation,
and death. Therefore, excitability and mTOR are
key endogenous neuroprotection mechanisms in
motoneurons to counteract clinically important dis-
ease progression in ALS.
INTRODUCTION
Neurodegenerative diseases can involve decades-long preclini-
cal phases of subtle pathologies (e.g., Reiman et al., 2004; Kok
et al., 2009) followed by relentlessly progressing neurodegener-
ation. Any intervention that could delay clinical disease onset
would have dramatic consequences on the burden of disease,80 Neuron 80, 80–96, October 2, 2013 ª2013 Elsevier Inc.but the mechanisms that influence early progression processes
are poorly understood (Palop and Mucke, 2010; Saxena and
Caroni, 2011). The study of early disease mechanisms in vivo
has been greatly aided by the availability of experimentally trac-
table animal models in which disease-related processes unfold
according to specific cellular patterns and predictable temporal
schedules. Nevertheless, dissecting disease-relevant causality
relationships has remained challenging, mainly due to the diffi-
culties inherent in discriminating underlying causes from adap-
tive consequences and harmless epiphenomena during slowly
progressing early phases of disease in vivo. Because disease-
related deficits might be neutralized initially through homeostatic
and compensatory processes, we hypothesize that adaptive
responses are likely to be predominant during early phases of
disease. Accordingly, the identification and investigation of
disease-relevant early dysfunction might benefit from a focus
on candidate endogenous neuroprotection mechanisms that
might compensate for mounting disease-related cellular mal-
functions. Taking such an approach here, we focused on the
early vulnerability of low-excitability fast-fatigable (FF) motoneu-
rons (MNs) in amyotrophic lateral sclerosis (ALS) (Pun et al.,
2006; Saxena et al., 2009; Kanning et al., 2010) and investigated
how excitability might relate to the early progression of pa-
thology and dysfunctions in mouse models of familial ALS. We
provide evidence that excitability and mammalian target of
Rapamycin (mTOR) together provide endogenous neuroprotec-
tion to familial amyotrophic lateral sclerosis (FALS) alpha-MNs
and that a growing deficit in excitability-related signaling drives
pathology and dysfunction in superoxide dismutase 1 (SOD1)
mouse models of FALS.
Transgenic mice overexpressing FALS-associated human
mutant SOD1 (mutSOD1) under the control of a human SOD1
promoter cassette have provided valuable animal models
to investigate mechanisms of disease in ALS (Gurney et al.,
1994; Boille´e et al., 2006; Kanning et al., 2010; Saxena and
Caroni, 2011). The mice exhibit characteristic MN disease fea-
tures, including long presymptomatic phases of increasing cell
specific pathology and dysfunction and rapidly progressing clin-
ical phases leading to paralysis and death. MN pathology in
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closely resembles sporadic cases of ALS (Boille´e et al., 2006;
Kanning et al., 2010), establishing mutant mice as valid genetic
models to investigate early mechanisms of disease in neurode-
generation. Notably, spinal alpha-MNpathology and dysfunction
develops in the mice with remarkable temporal reproducibility,
allowing the combination of data from individual mutant mice
of different ages into virtual longitudinal studies (Pun et al.,
2006; Saxena et al., 2009). These studies have provided evi-
dence that in SOD1-based FALS models, low-excitability FF
MNs innervating hind limb muscles abruptly prune their periph-
eral axonal arborizations within about 2 days (Pun et al., 2006).
Medium-excitability fatigue-resistant (FR) MNs disconnect
from the periphery 30 days later, whereas highly excitable
slow (S) MNs are resistant and only partially disconnect from
target muscles when mice reach end-stage paralytic disease
(Pun et al., 2006). In each alpha-MN subpopulation, the selective
denervation processes are preceded first by gradually
increasing endoplasmic reticulum (ER) stress, followed by an
unfolded protein response20 days before denervation (Saxena
et al., 2009), and by axonal pathology during the last 2 weeks
before denervation (Pun et al., 2006). Taken together, these
findings provided evidence for a higher vulnerability of low-
excitability FF MNs and a relatively higher resistance of high-
excitability S MNs in FALS mice. Available clinical data are
consistent with the notion that disease progression in ALS pa-
tients involves comparable differential vulnerabilities of low-
and high-excitability alpha-MNs (Kanning et al., 2010). Whether
the low excitability of FF MNs might account for their higher
vulnerability to degeneration has, however, remained unclear.
Early alterations in excitability have been reported in sporadic
and familial ALS, as well as in mouse models of FALS (Bories
et al., 2007; Vucic et al., 2008; Saxena and Caroni, 2011).
Reduced levels of astrocytic glutamate transporter and
enhanced excitability have led to the hypothesis that excessive
excitability and excitotoxicity might be major pathogenic factors
in ALS (Rothstein, 1995-1996; Van Den Bosch et al., 2006). On
the other hand, studies of cultured spinal MNs have revealed a
specific pathway affecting 50% of mutant MNs and to which
wild-type MNs and mutant non-MNs are immune (Raoul et al.,
2002; Kanning et al., 2010). Those results have implicated
excess MN cytosolic calcium and ER stress in FasL- and nitric
oxide-induced cell death upon downregulation of the ER calcium
sensor and chaperon Calreticulin in FALS MNs (Bernard-Maris-
sal et al., 2012). Calreticulin (Molinari et al., 2004) did not protect
wild-type MNs from activation of the FasL pathway, suggesting
that the vulnerability of alpha-MNs induced by mutSOD1 might
specifically involve calcium and ER pathways (Bernard-Marissal
et al., 2012). Reduced Calreticulin levels were mainly detected in
vulnerable FF MNs of tibialis anterior, but not in resistant MNs of
soleus in presymptomatic SOD1(G93A) mice, suggesting that
the specific calcium-related toxicity pathway also operates in
FALS MNs in vivo (Bernard-Marissal et al., 2012). The enhanced
cytosolic calcium levels might reduce the excitability of MNs
through the activation of calcium-dependent hyperpolarizing
conductances (Miles et al., 2007). Accordingly, MN excitability
signaling in ALS might primarily be reduced, not enhanced.
Furthermore, whereas ER stress in FALS (Kanekura et al.,2009; Saxena and Caroni, 2011) might be due to the accumula-
tion of misfolded proteins, alternative scenarios (e.g., including a
depletion of lumenal calcium in the ER) are also possible (Tu
et al., 2006; Wang and Kaufman, 2012). Taken together, these
considerations have suggested contrasting potential scenarios
of how alterations in excitability and ER stress might influence
early phases of disease in ALS, but whether and how any of
these have a role in disease progression has remained unclear.
Here, we investigated a possible role of excitability in disease
progression in presymptomatic FALS mice. We first established
antibodies against misfolded SOD1 (misfSOD1) (Gros-Louis
et al., 2010) as specific and sensitive cellular reagents to detect
disease-relevant pathology in early presymptomatic FALS
mice. We then provided evidence that disease-associated
SOD1 mutants specifically render alpha-MNs dependent on
endogenous neuroprotection signaling involving excitability
and mTOR. During a protracted presymptomatic phase, inhibit-
ing MN excitability was sufficient to induce comparable pathol-
ogy and enhanced compensatory responses in all vulnerable
alpha-MNs, suggesting that the relatively higher resilience of
FR and S alpha-MNs to disease is related to their comparatively
higher excitabilities. Enhancing MN excitability augmented neu-
roprotection pathways in FALS MNs. Modulating excitability or
alpha-MN mTOR influenced the progression rates of motor
dysfunction, muscle denervation, and death, providing evidence
that excitability and mTOR are key endogenous neuroprotection
mechanisms to counteract clinically important disease pro-
gression in FALS. Taken together, our results identify critical early
dysfunction processes in FALS MNs, providing support to the
notion that a focus on endogenous neuroprotection pathways
in presymptomatic mice provides a valuable approach to unravel
causal relationships between early disease-related dysfunctions
and corresponding compensatory responses. Their elucidation
might guide the elaboration of early therapeutic strategies in ALS.
RESULTS
Early Disease-Related Misfolded SOD1 Accumulation in
Vulnerable MNs
To monitor relevant neuronal dysfunction in presymptomatic
FALSmice, we first sought to establish specific early cellular dis-
ease-related markers. Because mutant SOD1 causes disease in
the transgenic mice, we reasoned that misfSOD1 accumulation
might provide an unbiased readout of the disease process.
Accordingly, we investigated misfSOD1 immunoreactivity using
conformation specific monoclonal antibodies D3H5 or A5C3,
which specifically detect disease-associated epitopes of this
ubiquitous cytosolic protein (Gros-Louis et al., 2010). Alpha-
MNs were identified as ventral horn cells, which were positive
for vesicular acetylcholine transporter (VAChT) or choline acetyl
transferase (ChAT) immunoreactivity, and were surrounded by
brightly labeled VAChT-positive C-boutons, the presynaptic
endings of cholinergic partition cells (Miles et al., 2007; Zagor-
aiou et al., 2009). Most of the experiments were carried out in
transgenic mice overexpressing moderate (TgG93Aslow; abbre-
viated as G93A-s) or high (TgG93Afast; abbreviated as G93A-f)
levels of human SOD1(G93A) under the control of a human
SOD1 minigene, but qualitatively comparable results wereNeuron 80, 80–96, October 2, 2013 ª2013 Elsevier Inc. 81
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Figure 1. Early Disease-Related Misfolded SOD1 Accumulation in Vulnerable MNs
(A) MisfSOD1 accumulation specifically in FALS MNs exhibiting high ER stress. Left: codistribution of misfSOD1 and BiP signals in FALS MNs and absence of
detectable signals in transgenic mice overexpressing wild-type human SOD1. Right: accumulation of misfSOD1 specifically in FALS MNs with high BiP signals.
Scale bars represent 100 mm (left), 25 mm (right).
(B) Age dependence of misfSOD1 accumulation in FALS MNs. IP-western: immunoprecipitation with misfSOD1 antibody and immunoblot with pan-SOD1
antibody. Quantitative analysis, misfSOD1-positive (+ve); MNs, percentage of VAChT-positive lumbar spinal cord ventral horn cells with detectable misfSOD1
accumulation; N = 3–5mice each; error bars represent SEM. *p < 0.05, **p < 0.01 ***p < 0.001 in post-ANOVA Tukey test (same for all figures); OD, optical density
for misfSOD1 signal (N = 3 mice each; bars represent SEM). Scale bar represents 50 mm.
(C) Accumulation of misfSOD1 and BiP signals specifically in most vulnerable FFMNs. Immunocytochemistry signal in back-labeled, rhodamine-dextran positive
MNs. N = 3 mice each; error bars represent SEM.
(D) Reduced MN misfSOD1 accumulation in mice treated with ER stress reducing agent Salubrinal (every second day, from P90 to P105). Quantitative analysis:
IP-western as in (B); signal in Salubrinal-treated mice expressed as percent of vehicle-treated mice (N = 3 mice; SEM). Scale bar represents 20 mm.
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SOD1(G85R) mutant.
Frompostnatal day (P) 7 on, but not yet at P1 (nor at embryonic
day 15), we detected a distinct misfSOD1 signal specifically in a
subpopulation of alpha-MNs in the lumbar spinal cord in mutant
mice (Figures 1A and 1B). NomisfSOD1 signals were detected in82 Neuron 80, 80–96, October 2, 2013 ª2013 Elsevier Inc.nontransgenic wild-type mice, or in transgenic mice over-
expressing human wild-type SOD1 at any age (TgwtSOD1
mice; Figure 1A). MN misfSOD1 signals remained confined to
40%–50% of lumbar spinal cord alpha-MNs until P55–60
(G93A-f) or P140–150 (G93A-s) (Figure 1B). Retrograde labeling
experiments involving rhodamine-dextran applied locally to
Neuron
Endogenous Neuroprotection Mechanisms in ALSidentified muscle compartments exclusively innervated by FF
(lateral gastrocnemius, subcompartment l1), or mixed FR + S
MNs (soleus) (Saxena et al., 2009) revealed that during this early
presymptomatic phase, misfSOD1 specifically accumulated in
FF MNs (Figure 1C). Consistent with the notion that misfolded
mutant protein accumulation was initially specifically confined
to the most vulnerable FF MNs, the distribution of the misfSOD1
signal among MNs closely resembled that of the ER chaperon
binding immunoglobulin protein (BiP) (Figure 1C), which specif-
ically accumulates in FF MNs in presymptomatic mice (Saxena
et al., 2009). Indeed, one of the antigens (A5C3) highlighted mis-
fSOD1 accumulation closely codistributed with ER (Figure 1A),
whereas D3H5 yielded more intense labeling signals that were
distributed throughout the cytosol of MNs. After this protracted
presymptomatic stage, and 5–10 days before an unfolded pro-
tein response (UPR) in FR MNs, the fraction of lumbar spinal
cord alpha-MNs positive for misfSOD1 increased to >80% of to-
tal, thus including FRMNs (Figure 1B). Consistent with a specific
disease association, MN misfSOD1 immunoreactivity signals
and ventral spinal cord immunoprecipitation (IP)-western levels
were reduced in early presymptomatic mutant mice (G93A-s,
P105; i.e., in FF MNs) treated with the anti-ER stress reagent
Salubrinal, which delays disease progression (Figure 1D; Saxena
et al., 2009). The Salubrinal treatment also abolished the codis-
tribution of A5C3 antigen with ER (not shown). We concluded
that in the FALS disease models MN pathology as revealed by
misfSOD1 accumulation is already detectable specifically in FF
MNs at 1 week of age (but not before) and becomes detectable
in FR MN shortly before the onset of the clinical phase.
Within a FALS Context alpha-MNs Depend on
Excitability to Prevent Pathology
To investigate early mechanisms of disease in FALS, we then
determined whether the higher relative vulnerability of FF MNs
might be related to their lower excitability and whether reducing
excitability might selectively compromise FALS alpha-MNs. In a
first set of experiments, we treated FALS mice with nonparalyz-
ing doses of the a-amino-3-hydroxy-5-methyl-4-isoxazolepro-
pionic acid (AMPA) receptor antagonist 6-cyano-7-nitroquinoxa-
line-2,3-dione (CNQX) and analyzed misfSOD1 accumulation
patterns in mutant mice that had been exposed to CNQX during
1, 3, 5, or 20 days. Up to 5 days of treatments had no detectable
effects in a grid test assay that measured muscle strength in
wild-type or FALS mice, indicating that at these doses CNQX
did not majorly affect MN firing activities (not shown). Never-
theless, the CNQX treatments had a dramatic impact on
misfSOD1 accumulation and ER stress in alpha-MNs. In early
presymptomatic mutant mice treated with CNQX for 1–3 days,
misfSOD1 accumulation increased strongly in MNs, where it
spread to most lumbar spinal alpha-MNs (Figure 2A). In parallel,
alpha-MNs exhibited massively elevated levels of ER chaperon
BiP and of the UPRmarker Pi-eIF2a (Figures 2A; Figure S1 avail-
able online). By contrast, the same treatments did not detectably
enhance misfSOD1, BiP, or Pi-eIF2a levels in non-MNs in the
spinal cord, or in other parts of the brain of SOD1 mutant mice
(Figure S1; not shown). Supporting the notion that reduced
excitability augments MN pathology in mutant SOD1 mice,
administration of the serotonin antagonists Ketanserin + Way(5-HT1A/2A) also rapidly augmented misfSOD1 accumulation
and ER stress in alpha-MNs (Figure 2A). N-methyl-D-aspartate
(NMDA) receptor inhibition with AP5 was as effective as CNQX
in augmenting alpha-MN misfSOD1 and ER stress, suggesting
that the dramatic increase in pathology specifically in alpha-
MNwas due to reduced excitability-related signaling (Figure 2A).
Unlike short-term treatments during 1–5 days, prolonged treat-
ments with CNQX during 20 days induced accumulation of mis-
fSOD1 and BiP in a majority of neurons in the spinal cord and in
the rest of the CNS in SOD1 mutant mice (Figure S1). Even a
prolonged attenuation of AMPA receptor transmission however
failed to induce signs of UPR outside alpha-MNs (Figure S1).
To determine whether alpha-MNs might be most affected by
reduced excitability specifically in a disease context, we deliv-
ered CNQX to TgwtSOD1 mice that ubiquitously overexpress
high levels of wild-type human SOD1 and only develop mild
MN pathology late in life (Figure S1). Up to five days of CNQX
did not induce any detectable ER stress or accumulation of
misfSOD1 in TgwtSOD1 alpha-MNs (Figure S1). Twenty days
of CNQX did induce a robust and closely comparable accumula-
tion of BiP immunoreactivity in spinal MNs and non-MNs but only
induced misfSOD1 accumulation and ER stress in few MNs in
the TgwtSOD1 mice (Figure S1). A 20 day regime of CNQX in
nontransgenic wild-typemice again induced closely comparable
accumulations of BiP in spinal MNs and non-MNs, albeit at lower
levels than in TgwtSOD1 mice (Figure S1). These results sug-
gested that although chronic reduction of excitability during
20 days induces comparable ER stress in all neurons and in all
genetic backgrounds, disease-related mutSOD1 greatly and
specifically sensitizes alpha-MNs to adverse effects of reduced
excitability.
To determine whether FALS neurons might be specifically
sensitized to reduced excitability as opposed to being generally
sensitized to stressors, we induced robust widespread ER stress
in early presymptomatic FALS mice by intraperitoneal injections
of Tunicamycin or Thapsigargin (Figure 2B). Two days later,
drug-treated mice exhibited strongly elevated levels of the ER
chaperon BiP in most spinal cord neurons (Figure 2C). By
contrast, massively elevated levels of misfSOD1 were specif-
ically induced in alpha-MNs, but were absent in other neurons
(Figures 2B and 2C). When tgwtSOD1 mice were subjected to
the same treatment, misfSOD1 accumulation was much less
pronounced than in FALS mice, but it was again restricted to
alpha-MNs (Figures 2B and 2C). Interestingly, cerebellar Purkinje
cells also exhibited selective misfSOD1 accumulation upon
enhanced ER stress in FALS and tgwtSOD1 mice (Figure 2B),
but they lacked detectable misfSOD1 signals in FALS mice
even upon 5 days of CNQX treatment (not shown, but see Fig-
ure S1 for 20 day CNQX treatment). These results revealed that
intense ER stress is not sufficient to induce misfSOD1 accu-
mulation in most FALS neurons and provided evidence for the
existence of a specific relationship between SOD1-related
pathology, excitability and stressors selectively in alpha-MNs
(Ezzi et al., 2007; Pokrishevsky et al., 2012).
Excitability Modulates Disease Progression in FALS
To investigate whether enhanced excitability might negatively
modulate the accumulation of FALS-related pathology in MNs,Neuron 80, 80–96, October 2, 2013 ª2013 Elsevier Inc. 83
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Figure 2. High Vulnerability Specifically of Spinal FALS Alpha-MNs to Reduced Excitability or ER Stress
(A) Short-term treatments with inhibitors of AMPA, NMDA, or 5HT receptors lead to enhanced ER stress andmisfSOD1 accumulation in most alpha-MNs of FALS
mice. N = 3 mice each; SEM. Scale bar represents 100 mm.
(B and C) Treatment with ER stress inducing agents Tunicamycin or Thapsigargin in transgenic mice overexpressing wild-type or mutant SOD1 induces BiP
expression in most neurons but misfSOD1 accumulation specifically in alpha-MNs and cerebellar Purkinje cells (B). Tuni, Tunicamycin; Tapsi, Thapsigargin.
Quantitative analysis (C). N = 3 mice each; SEM. Scale bar represents 150 mm (B).
See also Figure S1.
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agonist AMPA. AMPA greatly reduced the accumulation of mis-
fSOD1 in alpha-MNs of presymptomatic and symptomatic
mutant SOD1 mice (Figure 3A). Furthermore, AMPA significantly
reduced the accumulation of ER stress and UPR markers in pre-
symptomatic mice, albeit not at more advanced phases of dis-
ease (Figure 3A). Interestingly, AMPA was comparably effective
in reducing misfSOD1 accumulation when drug administration
regimes were started at early or late presymptomatic stages
(Figure 3A), suggesting that misfSOD1 accumulation in FALS
alpha-MNs is a dynamic process, which can be reversed by
enhanced excitability. Notably, AMPA counteracted the downre-
gulation of Calreticulin in FF MNs (Figure 3B), the ER chaperon84 Neuron 80, 80–96, October 2, 2013 ª2013 Elsevier Inc.and lumenal calcium sensor, which is a disease-specific trigger
of dysfunction and death in selectively vulnerable FALS alpha-
MNs (Bernard-Marissal et al., 2012). Taken together, these
results provided evidence that although reduced excitability
specifically aggravates disease-related pathology in FALS
alpha-MNs, enhanced excitability can specifically protect the
same vulnerable alpha-MNs.
To investigate whether AMPA promotes neuroprotection
pathways in presymptomatic FALS MNs, we monitored
accumulation levels of the calcium-dependent neuroprotection
proteins GADD45b, DREAM, and Btg2 (Zhang et al., 2009) in
wild-type and G93A-f mice. MN GADD45b immunoreactivity
was elevated in FALS compared to wild-type MNs (Figure 3C).
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Figure 3. AMPA Receptor Agonist Treatment in FALS Mice Enhances Neuroprotection Pathways in MNs, Protects alpha-MNs against
Pathology, and Delays Degeneration and Death
(A) AMPA protects alpha-MNs against pathology in presymptomatic FALS mice. N = 3 mice each; SEM; AMPA every second day for 20 days. Scale bar rep-
resents 150 mm.
(B) AMPA prevents downregulation of Calreticulin in alpha-MNs of FALS mice. N = 3 mice each; SEM. Scale bar represents 100 mm.
(C) Activation of neuroprotection pathway in MNs by AMPA and inhibition by CNQX. N = 6 mice each (P31; 6 days of treatment, daily); SEM.
(D–F)AMPApreventsdecline in force (D),AMPAdelaysandCNQXacceleratesdenervationbyFRandSMNs (E),anddeath (F) inFALSmice.N=3–5miceeach;SEM.
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Endogenous Neuroprotection Mechanisms in ALSDaily AMPA treatments from P25 to P31 enhanced MN
GADD45b signals, and this effect was much more pronounced
in FALS than in wild-type MNs (Figure 3C). Conversely,
CNQX reduced MN GADD45b, and the effect of CNQX was
more pronounced in wild-type MNs (Figure 3C). AMPA thus
enhances the levels of endogenous neuroprotection protein
GADD45b in MNs and this upregulation is specifically poten-
tiated in FALS MNs. In contrast to GADD45b, DREAM levels
were substantially reduced in FALS MNs compared to wild-
type values (Figure 3C). AMPA restored FALS MN DREAM
signals to nearly wild-type values, whereas it did not affect
DREAM signals in wild-type MNs (Figure 3C). Likewise, CNQX
substantially reduced DREAM signals in FALS, but did not
affect DREAM signals in wild-type MNs (Figure 3C). Endo-
genous neuroprotection mechanisms involving DREAM are
thus specifically downregulated in FALS MNs, where they are
rescued by AMPA and further reduced by CNQX. Finally, Btg2
levels were markedly elevated in FALS MNs, suggesting activa-
tion of endogenous neuroprotection pathways (Figure 3C).
AMPA restored FALS MN Btg2 to nearly wild-type values,
whereas CNQX had no detectable effect (Figure 3C). Taken
together, these results provided evidence that AMPA enhances
neuroprotection specifically in FALS MNs as revealed by poten-
tiated GADD45b enhancement and by restored FALS MN
DREAM levels. The results further suggested that activation of
additional neuroprotection pathways in FALS MNs led to
elevated Btg2 levels, which were restored to nearly wild-type
values by AMPA.
We next determined whether altering AMPA receptor activa-
tion also affects clinically relevant disease progression in
mutant SOD1 FALS mice. Mutant mice were treated with
CNQX or with AMPA from P40 (G93A-s) or P20 on (G93A-f),
and we compared sustained force (grid test), peripheral dener-
vation, and survival in drug-treated and vehicle-treated cohorts.
The treatments did not detectably affect total hSOD1 or total
pan-SOD1 (mouse plus human) signals in MNs (not shown,
but see below). CNQX accelerated force loss (not shown),
denervation (Figure 3E) and death (Figure 3F) by 30 days in
mutant SOD1 mice. Prolonged treatments with CNQX did not
induce noticeable force loss or denervation in tgWTSOD1
mice, further supporting the notion that reduced excitability
aggravates pathology specifically within a disease background
(not shown). Conversely, AMPA markedly improved force (Fig-
ure 3D), delayed FR and S denervation (Figure 3E), and
extended survival by 20–35 days (Figure 3F) in mutant SOD1
mice. Although denervation by resistant FR and S MNs was
substantially delayed by the AMPA receptor treatments, dener-
vation by FF MNs was not detectably affected (not shown, but
see below). Likewise, although AMPA receptor activation or in-
hibition modified the timing of peripheral denervation and clin-
ical manifestations of disease, the same treatments did not alter
the specific patterns of progressive deficits involving first the
least excitable FF MNs, then FR MNs, and finally the most excit-
able S MNs. Taken together, these results provided evidence
that the status of chronic AMPA receptor activation can modu-
late disease progression in FALS mice. The results further sug-
gested that FALS FF MNs might be least effective in harnessing
neuroprotection through excitability.86 Neuron 80, 80–96, October 2, 2013 ª2013 Elsevier Inc.Cell Autonomous Neuroprotection by Excitability in
FALS MNs
To determine whether excitability specifically of MNs influences
misfSOD1 accumulation and disease-related pathology in FALS
mice we carried out pharmacogenetic experiments in vivo.
Floxed pharmacologically selective actuator module (PSAM)
either coupled to 5HT3-receptor (PSAM-Act) for neuronal depo-
larization or to glycine-receptor (PSAM-Inh) for neuronal hyper-
polarization (Magnus et al., 2011) was expressed unilaterally in
lumbar spinal cord alpha-MNs (ChAT-Cre mice) or Parvalbu-
min-positive interneurons (PV) (PV-Cre mice) using AAV9 viral
vectors. Expressed channels were then activated using a
specific ligand (Magnus et al., 2011). Unilateral channel expres-
sion in individual MNs or PV neurons, including PSAM-express-
ing PV boutons adjacent to alpha-MNs, could be readily
detected with fluorescently labeled a-Bungarotoxin (Figure 4A).
Enhancing MN excitability or reducing PV neuron excitability
(disinhibition of MNs) specifically reduced misfSOD1 and BiP
accumulation in ipsilateral FALS alpha-MNs (Figures 4B and
4C). A detailed analysis revealed that reduced misfSOD1 and
BiP accumulation were specifically associated with individual
PSAM-expressing MNs within ipsilateral ventral horn (not
shown). Total MN hSOD1 signals were not affected in these
experiments (Figure 4C). Conversely, reducing MN excitability
specifically enhancedmisfSOD1 and BiP accumulation in ipsilat-
eral FALS alpha-MNs (Figures 4B and 4C). In control experi-
ments, the same pharmacogenetic treatments did not affect
ER stress markers in wild-type MNs (not shown). In parallel to
reducingmisfSOD1 andBiP accumulation, MNactivation specif-
ically enhanced levels of neuroprotective proteins GADD45b and
DREAM and decreased Btg2 levels in ipsilateral FALS MNs (Fig-
ure 4D). Finally, prolonged pharmacogenetic activation of FALS
MNs specifically reduced pEIF2a accumulation (UPR) and
delayed muscle denervation by FF MNs (Figure 4E). Taken
together, these results provided evidence that enhanced excit-
ability of MNs cell autonomously promotes neuroprotection
and delays disease manifestations in FALS MNs.
Altered Signaling to CREB in Affected FALS MNs
To investigate whether intracellular signaling related to excit-
ability might be altered in FALS alpha-MNs, we analyzed MN
levels of phosphorylated (Ser133) cAMP response element-
binding protein (pCREB), an activity-sensitive readout for alter-
ations in calcium, MAP-kinase, and cAMP pathways in neurons
(Greer and Greenberg, 2008). In young presymptomatic FALS
mice, pCREB levels within MNs were markedly reduced
compared to wild-type mice (Figure 5A). Retrograde labeling
revealed that FF MNs exhibited highest pCREB levels among
alpha-MNs in resting wild-type mice and that it was specifically
FF MNs that exhibited lower pCREB levels in resting FALS
mice (Figure 5A). Exercise failed to enhance pCREB levels in
FALS MNs (Figure 5A), suggesting diminished excitation-related
signaling to CREB in FALSMNs. AMPA reduced pCREB levels in
MNs of wild-type and mutant SOD1 mice to comparable levels
(Figure 5A). Wild-type and mutant mice treated with the seroto-
nin agonists quizapine (5-HT2A) and 8OH-DPAT (5-HT1A/7) also
exhibited comparable and substantially reduced pCREB levels
in alpha-MNs (Figure 5A), suggesting that enhanced excitability
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Figure 4. Pharmacogenetic Enhancement of MN Excitability Cell Autonomously Protects FALS MNs
(A) Visualization of PSAM expression in lumbar spinal cord MNs and PV+ interneurons. Note unilateral expression; contralateral expression was restricted to
contralaterally extending trunk MNs and PV+ neurons. Inset: PV+ boutons (green) surrounding BiP+ (white)/VAchT-decorated MN.
(B and C) Modulation of misfSOD1 and BiP accumulation in MNs by pharmacogenetically controlled excitability. Total MN hSOD1 signals were not affected (B).
Quantitative analysis (C). N = 5 mice each (ipsilateral and contralateral MNs); SEM.
(D) Activation of neuroprotection pathways in FALS MNs upon enhanced MN excitability. N = 4 mice each; SEM. Scale bar represents 20 mm.
(E) Pharmacogenetic enhancement of MN excitability delays UPR in FFMNs and denervation in FFmuscle subcompartment. N = 3 (denervation) and N = 4 (UPR)
mice each; SEM. Scale bar represents 100 mm.
Neuron
Endogenous Neuroprotection Mechanisms in ALScan neutralize pCREB differences between wild-type and FALS
alpha-MN, and reduced pCREB levels in FALS FF MNs at rest
might reflect enhanced excitability in these most vulnerable
alpha-MNs in early presymptomatic mice.Enhanced Excitability Connectivity onto FALS MNs
To investigate whether endogenous alterations in excitability
connectivity might counteract disease progression in FALS
MNs, we analyzed the distribution of synapses that control theNeuron 80, 80–96, October 2, 2013 ª2013 Elsevier Inc. 87
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Figure 5. Enhanced Excitability Connectivity onto Vulnerable MNs in FALS Spinal Cord
(A) Reduced pCREB levels in vulnerable FALS FF MNs mimicked by enhanced excitability. Left: retrograde labeling experiment for FF MNs. Note lower pCREB
signals in FALS MNs (P32 data). Center left: individual ventral spinal cord MN pCREB signal intensity values (individual dots) from four mice each. Values for
vulnerable FF or resistant Soleus MNs identified through retrograde labeling. Center right: average pCREB signal intensity values in wild-type and FALS MNs
under resting conditions (Ctrl) and upon treadmill exercise (Exc.); N = 3 mice each; SEM. Right: quantitative analysis; average MN pCREB values for lowest and
highest quartiles; N = 3 mice each; SEM. Drug treatments during 2 days. Scale bar represents 50 mm.
(B) Reduced densities of Gephyrin-positive puncta (putative GABAergic synapses) in ventral horn of lumbar spinal cord in FALS mice. N = 3 mice each; SEM.
Scale bar represents 25 mm.
(C) Elevated densities of 5HT-positive boutons around alpha-MNs of FALS mice. N = 3 mice each; SEM Scale bar represents 12.5 mm.
(D) Enlarged cholinergic C-boutons surrounding alpha-MNs of FALS mice. N = 3 mice each. Scale bar represents 12.5 mm.
(E) Enlarged C-boutons specifically surrounding vulnerable MNs with enhanced ER stress in presymptomatic FALSmice. Quantitative analysis (individual bouton
sizes) from three mice. Scale bar represents 12.5 mm.
(F) AMPA receptor inhibition with CNQX produces further enlargement of C-boutons in FALS mice. CNQX treatment during 5 days; N = 3 mice each; SEM. Scale
bar represents 12.5 mm.
Neuron
Endogenous Neuroprotection Mechanisms in ALSexcitability of alpha-MNs in FALS mice. We did not detect
obvious alterations in the sizes or densities of sensory afferent
VGlut1 puncta onto MN somas and proximal dendrites (not
shown). By contrast, we found that ventral horn gephyrin puncta
densities were 60%–65% of wild-type values (Figure 5B), sug-
gesting a major reduction of inhibitory synapse densities onto
mutant MNs at early stages of disease. Furthermore, ventral spi-
nal cord densities of serotonergic boutons, which positively
modulate MN excitability and motor output, were significantly88 Neuron 80, 80–96, October 2, 2013 ª2013 Elsevier Inc.elevated in presymptomatic SOD1 mutant mice (Figure 5C).
Finally, metabotropic cholinergic C-bouton puncta onto mutant
MNs, which also positively modulate MN excitability, were on
average substantially larger than in wild-type mice (Figure 5D;
see also Pullen and Athanasiou, 2009). These observations sug-
gested the presence of a larger excitability drive onto MNs in
early presymptomatic mutant spinal cords.
A more detailed examination of C-bouton size distributions
onto individual MNs suggested that only a fraction of the MNs
Neuron
Endogenous Neuroprotection Mechanisms in ALSwere contacted by enlarged C-boutons in the mutant mice.
Retrograde labeling experiments revealed that in wild-type
mice C-boutons contacting FF MNs were larger than those con-
tacting FR or S MNs (not shown) and that it was specifically the
C-boutons onto MNs with high BiP signals that were further
enlarged in young mutant FALS mice (Figure 5E). An analysis
of C-bouton sizes versus age revealed that disease-related
enlargement was confined to FF MNs up to their denervation
time in G93A-f and G93A-s mice, when it then extended to a
majority of alpha-MNs (not shown). Consistent with a recent
report (Herron and Miles, 2012), and with a somewhat more
severe progression of disease in male FALS mice, C-bouton
enlargements appeared with an 8–10 day delay and were less
pronounced in female FALS mice (not shown). CNQX treatment
produced C-bouton enlargements in a majority of alpha-MNs in
young presymptomatic FALS mice (Figure 5F), supporting the
notion that delayed C-bouton enlargement and pathology in
FR MNs were related to their higher intrinsic excitability
compared to FFMNs. Taken together, these results were consis-
tent with the notion that in FALS mice enhanced excitability
connectivity might be induced to provide more effective neuro-
protective signaling to vulnerable FALS alpha-MNs.
Neuroprotection in FALS Mediated through Cholinergic
C-Bouton Signaling
To investigate endogenous neuroprotective mechanisms that
counteract disease progression in FALS mice, we focused on
the possible role of C-bouton-mediated neurotransmission
onto MNs. Metabotropic transmission at these perisomatic
synapses leads to inhibition of calcium-dependent potassium
channels, possibly counteracting inhibitory effects of enhanced
cytosolic calcium on alpha-MN excitability (Miles et al., 2007; Za-
goraiou et al., 2009). Furthermore, these large cholinergic bou-
tons are associated with abundant ER membrane systems
closely associated with the postsynaptic membrane, and their
enlarged sizes onto the most vulnerable MNs suggested a spe-
cific role early in disease (Pullen and Athanasiou, 2009). To deter-
mine whether the larger size of C-boutons onto vulnerable MNs
of mutant SOD1 mice might occur in response to a deficit in
excitability signaling, we analyzed C-bouton size distributions
in mice treated with CNQX (Figure 6A). Treating wild-type mice
with CNQX produced a substantial and apparently general
enlargement of C-boutons (Figures 5F and 6A), whereas AMPA
induced a general shrinkage of C-boutons in wild-typemice (Fig-
ure 6A). By contrast, reducing ER stress with Salubrinal or
enhancing ER stress with Tunicamycin did not influence C-
bouton sizes in wild-type or FALS mice (Figure 6A) suggesting
that C-bouton sizes adjusted specifically to excitability signaling
deficits and not to disease-related ER stress.
To investigate the role of neurotransmission through C-
boutons in disease progression, we treated mice with either an
antagonist (Methoctramine) or agonist (Oxotremorine) of the
type-2 metabotropic ACh receptor, which specifically mediates
cholinergic transmission at C-boutons (Miles et al., 2007).
Administration of Methoctramine in early presymptomatic
FALS mice produced a dramatic increase and spread of mis-
fSOD1 accumulation to most spinal alpha-MNs (Figure 6B). Sur-
prisingly, methoctramine at the same time strongly reduced ERstress and delayed UPR (Figure 6B). Methoctramine initially
delayed force loss in presymptomatic mutant mice (Figure 6C),
but it later accelerated denervation (Figure 6C), loss of force (Fig-
ure 6C) and death (not shown). Conversely, Oxotremorine
enhanced BiP signals in MNs (Figure 6D), enhanced UPR in FF
MNs (not shown), but did not significantly influence the accumu-
lation of misfSOD1 in FALS MNs (Figure 6D). Oxotremorine
delayed denervation (Figure 6E) late loss of force and death
(see below) in mutant SOD mice. Although indirect effects of
these pharmacological experiments targeting M2 receptors
cannot be excluded, the results were consistent with the notion
that C-bouton transmission influences disease-related pathol-
ogy, both in low-excitability FF MNs with enlarged C-boutons,
as well as in more resistant FR and S MNs without enlarged
C-boutons. In addition, the results revealed a dramatic and
unexpected dissociation between the accumulation of mis-
fSOD1 and ER stress in FALS MNs, suggesting that meta-
botropic cholinergic transmission might influence additional
pathways in FALS MNs, accounting for reduced misfSOD1
accumulation and neuroprotection.
Central Neuroprotective Role of mTOR in FALS MNs
In a search for additional neuroprotective pathways that might
be activated by metabotropic cholinergic transmission, we
noticed that phospho-S6 (pS6) immunoreactivity was specif-
ically elevated in thoseMNs that exhibited elevated levels of mis-
fSOD1 and BiP (Figure 7A). The elevated pS6 levels reflected
enhanced activation of mTOR in those vulnerable MNs, as
demonstrated by suppression upon administration of the
mTOR inhibitor Rapamycin (Figure 7B), by the concomitant
accumulation of the specific mTOR pathway markers p4EBP
and pTOR (not shown) and by increased levels of the autophagy
markers ATG6/Beclin (Figure 7B) and LC3 (not shown) in FALS
MNs upon Rapamycin treatment. FALS MN Btg2 upregulation
was abolished in Rapamycin-treated mice (Figure 7B), indicating
that it depended on mTOR activation. Elevated pS6 and Btg2
signals were detected in FF MNs from the earliest time points
included in our analysis (P15), and increased gradually, in close
correspondence with misfSOD1 and BiP, and with larger C-bou-
tons, first exclusively in FF and later also in FR and S MNs (Fig-
ure 7C). Methoctramine suppressed and oxotremorine
enhanced pS6 (and Btg2, not shown) accumulation in vulnerable
MNs (Figure 7D), suggesting that mTOR activation in FALS MNs
specifically depended on C-bouton transmission. MN pS6 levels
were substantially enhanced by CNQX, suggesting that the C-
bouton-mTOR-Btg2 pathway might be activated in FALS MNs
in response to a deficit in neuroprotection signaling (Figure 7E).
To determine whether mTOR protects vulnerable MNs against
pathology induced by mutant SOD1, we chronically treated
FALS mice with Rapamycin and analyzed disease markers in
vulnerable MNs. Rapamycin produced a dramatic accumulation
of misfSOD1, as well as UPR in most spinal alpha-MNs of
presymptomatic mutSOD1 mice (Figure 8A) and a pronounced
downregulation of Calreticulin in spinal MNs of presymptomatic
FALS mice (Figure 8B), suggesting that the mTOR pathway
is critically important to counteract disease-specific pathology
in FALS NMs. By contrast, and consistent with the notion that
a disease setting involving mutSOD1 specifically rendersNeuron 80, 80–96, October 2, 2013 ª2013 Elsevier Inc. 89
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Figure 6. Modulation of Metabotropic Cholinergic Signaling in FALSMice Reveals Dissociation of misfSOD1 Accumulation and ER Stress in
Vulnerable MNs
(A) C-bouton size is inversely correlated to excitability and is not affected by ER stress. N = 100 C-boutons from three mice each; SEM.
(B) Inhibiting metabotropic cholinergic signaling with Methoctramine enhances misfSOD1 accumulation but greatly reduces ER stress in FALS MNs. IP-western:
G93A-s mice at P75, previously treated with vehicle or Methoctramine during 15 days. N = 4 mice each; SEM. Scale bar represents 50 mm.
(C)Methoctramine alleviates force loss in early presymptomatic FALSmice, but accelerates denervation by resistantMNs and accelerates force loss in end-stage
mice. N = 3 mice (Soleus innervation) and N = 5 mice (force); SEM.
(D) Enhancing metabotropic cholinergic signaling with Oxotremorine augments ER stress, but does not significantly affect misfSOD1 accumulation in FALSMNs.
N = 3 mice each; SEM. Scale bar represents 100 mm.
(E) Oxotremorine delays Soleus denervation in FALS mice. N = 4 mice each; SEM.
Neuron
Endogenous Neuroprotection Mechanisms in ALSalpha-MNs dependent on neuroprotection involving mTOR, Ra-
pamycin did not induce ER stress in alpha-MNs of wild-type
mice (Figure S1).
To determine whether endogenous mTOR activation protects
against clinical aspects of disease progression in mutant SOD1
mice, we compared cohorts of mice treated with Rapamycin or90 Neuron 80, 80–96, October 2, 2013 ª2013 Elsevier Inc.vehicle. Rapamycin produced a complete denervation of soleus
muscle at P75 in G93A-fmice (Figure 8C), indicating that dener-
vation of FR and S MNs in the mutant mice was accelerated by
20 and 60 days, respectively. Furthermore, treating mutant
SOD1 mice with Rapamycin decreased survival by 30 days
(not shown; N = 5 mice each, p < 0.001). By contrast, and
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Figure 7. Early mTOR Activation Specifically in Vulnerable FALS MNs and Dependence on Metabotropic Cholinergic Signaling
(A) Accumulation of pS6 and Btg2 immunoreactivity specifically in vulnerable (high BiP, high misfSOD1) FALS MNs. Scale bar represents 50 mm.
(B) mTOR activation in vulnerable FALS MNs and mTOR-dependent expression of calcium-regulated neuroprotective transcriptional coactivator Btg2. Rapa-
mycin treatment: 15 days. Scale bar represents 50 mm.
(C) Disease-related accumulation of pS6 and Btg2 in vulnerable FALS MNs. N = 3–5 mice each; SEM.
(D) Metabotropic cholinergic signaling loops: mTOR activation in FALS MNs depends on metabotropic cholinergic signaling, and C-bouton volume is positively
modulated by M2 and mTOR signaling. N = 3 mice and 100 C-boutons each; SEM. Scale bar represents 50 mm.
(E) Chronic inhibition of AMPA receptor activation induces ER stress in most FALS neurons, but enhanced mTOR activation only in FALS MNs. Scale bar
represents 100 mm.
Neuron
Endogenous Neuroprotection Mechanisms in ALSconsistent with the notion that vulnerable MNs depend on active
mTOR for neuroprotection specifically within a FALS setting,
chronic treatment of wild-type mice with Rapamycin did not de-
tectably affect peripheral innervation (Figure S1) or survival (not
shown). Taken together, these results suggested that metabo-
tropic cholinergic transmission promotes distinct processes in
MNs, with opposite impacts onMN pathology in a FALS context;
these include neuroprotective mTOR activation and pathology-
enhancing ER stress activation.
To determine whether mTOR activation downstream of me-
tabotropic cholinergic transmission is important to protect
MNs in disease, we analyzed mutant SOD1 mice treated chron-ically with Oxotremorine to stimulatemTOR and at the same time
with Salubrinal to reduce the concomitant elevation of ER stress.
The dual treatment dramatically delayed pathology and clinical
manifestations in FALS mice. Thus, Oxotremorine + Salubrinal
greatly reduced the accumulation of misfSOD1 (Figure 8D),
reduced ER stress markers (Figure 8D), and delayed UPR (not
shown), while preserving elevated levels of pS6 and Btg2 (not
shown) in FALS MNs. In parallel, Oxotremorine + Salubrinal de-
layed peripheral denervation of FR and S MNs by at least
40 days, substantially counteracted force loss, and extended
survival by 50 ± 9 days (N = 8 mice each, p < 0.0001) in the
FALS mice (Figure 8E).Neuron 80, 80–96, October 2, 2013 ª2013 Elsevier Inc. 91
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15 days. N = 3 mice each; SEM. Scale bar represents 50 mm.
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Endogenous Neuroprotection Mechanisms in ALSDISCUSSION
We have investigated early mechanisms of disease in SOD1
mouse models of FALS, focusing on endogenous neuroprotec-
tion mechanisms and the selective vulnerability of alpha-MNs.
We provide evidence that disease-associated SOD1 mutants
specifically render vulnerable MNs dependent on endogenous
neuroprotection signaling involving MN excitability and mTOR.
The most vulnerable low-excitability FF MNs exhibited evidence
of pathology and neuroprotection recruitment from P7–14 on,
which included increasing accumulation of misfSOD1 and
enhanced mTOR activation. Enhancing MN excitability was
sufficient to reverse misfSOD1 accumulation, whereas blocking
metabotropic cholinergic signaling greatly enhanced misfSOD1
accumulation in alpha-MNs but reduced ER stress, suggesting
that ER stress is not directly caused by misfSOD1 accumulation
in FALS (Figure 8F). During a protracted presymptomatic phase,
inhibiting excitability was sufficient to induce comparable
pathology and enhanced neurocompensatory responses in
most alpha-MNs, but not in other neurons in FALS mice,
suggesting that the relatively higher resilience of FR and
S alpha-MNs to disease is related to their comparatively higher
excitabilities. Modulating excitability and/or alpha-MN mTOR
influenced the progression rates of motor dysfunction, muscle
denervation, and death, providing evidence that excitability
and mTOR are key endogenous mechanisms to counteract
clinically important disease progression in FALS (Figures 8F
and 8G). In the following sections, we discuss the main
implications of these results and how they relate to those of
previous studies addressing mechanisms of disease in
neurodegeneration.
Selective Vulnerability of MNs to SOD-Mediated
Neurodegeneration
Our results provide insights as to how MNs are selectively
affected in FALS. Because most neurons accumulated mis-
fSOD1 in FALS mice treated chronically with CNQX, but not in
tgwtSOD1 mice, our results do not support the notion that this
ubiquitously expressed mutant protein specifically affects
alpha-MNs. Instead, our results suggest that SOD1mutants alter
aspects of homeostasis signaling related to excitability that are
particularly consequential in vulnerable alpha-MNs (Figure 8G).
Thus, short-term global inhibition of excitability during
1–3 days in mutant SOD1 FALS mice induced misfSOD1 accu-
mulation and a robust UPR in most alpha-MNs, but not in other
neurons in the spinal cord or in the brain. Furthermore, direct
pharmacogenetic inhibition of excitability in MNs enhanced(B) Rapamycin induces further reduction of Calreticulin expression in FALS MNs
(C) Accelerated denervation by resistant Soleus MNs upon Rapamycin treatmen
(D) Combination treatment with Oxotremorine and Salubrinal greatly reduces mis
duration: 15 days. N = 4 mice each; SEM. Scale bar represents 100 mm.
(E) Delayed Soleus denervation, force loss and death in FALS mice treated with
each; SEM.
(F) Summary of how MN excitability and metabotropic cholinergic signaling influe
(G) Proposed model of vulnerable MN sensitization to stressors and role of end
processes in blue, against gray background. CRT: Calreticulin; Glu, 5HT, GABA
Metabotropic cholinergic activation also enhances ER stress, and enhanced exc
See also Figure S2.misfSOD1 accumulation and ER stress in those MNs. Taken
together, our findings suggest that in mutSOD1 models of
FALS vulnerable alpha-MNs are highly sensitized to cellular
stressors and specifically depend on endogenous excitability
and mTOR to delay clinically relevant disease progression
(Figure 8G). This sensitization model of motoneuron disease
pathophysiology suggests that the signaling and homeostasis
networks of vulnerable alpha-MNs include specific features
that render these neurons more susceptible to neurodegenera-
tion pathways (Kanning et al., 2010; Saxena and Caroni, 2011).
Thesemight be closely linked to calcium homeostasis processes
(von Lewinski and Keller, 2005; Kanning et al., 2010; Bernard-
Marissal et al., 2012). Themodel is reminiscent of findings in Par-
kinson’s, Alzheimer’s, and Huntington’s disease studies, in
which specific neuronal vulnerabilities have also been related
to selective degeneration (Bezprozvanny and Mattson, 2008;
Mosharov et al., 2009; Saxena and Caroni, 2011; Gleichmann
et al., 2012). As discussed below, alterations in calcium fluxes
and excitability signaling might be a common pathogenic signa-
ture of neurodegenerative diseases.
Although our results suggest that the particular vulnerability of
alpha-MNs to neurodegeneration involves excitability-related
pathways, the specific homeostasis and signaling pathway fea-
tures that account for this higher vulnerability remain to be deter-
mined. The conclusions of our study in FALSmice are consistent
with those of previous studies reporting that vulnerable FALS
MNs in vitro are specifically susceptible to cell death induced
by Fas-ligand and nitric oxide, whereas wild-type MNs or other
FALS neurons are not (Raoul et al., 2002). Like the present study,
those studies concluded that FALS MNs acquire a vulnerability
to specific stressors not present in wild-type MNs. Those
studies further provided evidence that elevated cytosolic cal-
cium levels and loss of Calreticulin are critical determinants of
enhanced vulnerability in cultured FALS MNs, leading to ER
stress and cell death (Bernard-Marissal et al., 2012). We
detected similar Calreticulin downregulation correlated with
advancing pathology and inhibited by excitability and mTOR in
our study, consistent with the notion that imbalances in alpha-
MN calcium homeostasis might underlie disease progression
in FALS mice (Figure 8G).
Endogenous Neuroprotection Analysis Reveals
Mechanisms of Disease Progression
Our longitudinal study in FALS mice provides experimental
evidence as to endogenous neuroprotection mechanisms that
delay pathology and dysfunction in FALS and suggests that a
deficit in excitability signaling in vulnerable alpha-MNs might. N = 3 mice each; SEM. Scale bar represents 25 mm.
t (20 days). N = 3 mice each; SEM. Scale bar represents 100 mm.
fSOD1 accumulation and ER stress in presymptomatic FALS mice. Treatment
Oxotremorine and Salubrinal. All treatments were from P30 on. N = 8 mice
nce pathology in FALS MNs. Endogenous neuroprotection processes in blue.
ogenous neuroprotection mechanisms in FALS. Endogenous neuroprotection
/Gly, C-boutons: synaptic pathways promoting endogenous neuroprotection.
itability might also augment neurotoxicity.
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ous reports, our findings suggest that the well-documented early
hyperexcitability of MNs in ALS (Vucic et al., 2008; Piotrkiewicz
and Hausmanowa-Petrusewicz, 2011; Martin and Chang,
2012) might represent an adaptive response to boost neuropro-
tective signaling in alpha-MNs (see also Gordon et al., 2010).
Indeed, initial hypoexcitability of FALS MNs has been reported
by some studies (Bories et al., 2007). At the same time, however,
hyperexcitability might contribute to aggravate disease loads on
MNs through excitotoxicity mechanisms (Rothstein, 1995-1996;
Van Den Bosch et al., 2006; Gleichmann et al., 2012). Our results
further provide a conceptual framework to account for the partic-
ularly high vulnerability of low-excitability FF MNs to disease
(Pun et al., 2006; Saxena et al., 2009). The results suggest that
in addition to being affected earliest in disease, high-threshold
FF MNs might be less effective in coupling excitability to neuro-
protection, leading to less effective delay of denervation with
AMPA or Oxotremorine + Salubrinal in FF MNs. Comparable
vulnerability sequences involving first FF and last S MNs have
also been reported for the juvenile motoneuron disease SMA
and for motoneuron dysfunctions associated with aging (Kan-
ning et al., 2010; Valdez et al., 2012), suggesting that signaling
related to excitability might be a central target of dysfunction in
neurodegenerative conditions affecting MNs (Mentis et al.,
2011; Imlach et al., 2012).
Contrary to some (Ravikumar et al., 2004), but not all (Zhang
et al., 2011; Kim et al., 2012; Selvaraj et al., 2012) previous
studies on the role of mTOR signaling in neurodegeneration,
our results provide evidence that mTOR activity is critically
important to delay disease progression in FALS. mTOR-depen-
dent accumulation of the potent neuroprotective gene Btg2, a
calcium-induced transcriptional coregulator, suggests that
mTOR signalingmight be required to boost compromised neuro-
protective signaling pathways in FALS MNs, thereby synergizing
with excitability signaling (Greer and Greenberg, 2008; Zhang
et al., 2009; Hardingham and Bading, 2010) (Figures 8F and
8G). EnhancingMN excitability was sufficient to reverse Btg2 up-
regulation, suggesting that a protective mTOR-Btg2 pathway is
augmented in FALS MNs upon a deficit in neuroprotective
signaling through excitability. Given that Rapamycin appears to
be protective in some neurodegenerative settings (e.g., by
relieving a brake on autophagy), the mTOR pathway might pro-
vide neuroprotection specifically within certain disease contexts
including FALS, but might interfere with neuroprotection in a
different subset of disease contexts. Our findings further suggest
that although misfSOD1 accumulation is a valuable biomarker of
disease (Bosco et al., 2010) (Figure 8G), it might not directly pro-
mote disease progression. Indeed, one interpretation consistent
with our results is that misfSOD1 accumulation in MNs might be
part of a cellular defense process to trap and neutralize dysfunc-
tional components in larger aggregates (Arrasate et al., 2004).
The accumulation of misfSOD1 was most closely correlated to
a deficit in excitability signaling in vulnerable FALS MNs (Piotr-
kiewicz and Hausmanowa-Petrusewicz, 2011), suggesting that
mutSOD1 might interact and interfere with molecular compo-
nents involved in neuronal excitability, e.g., proteins affecting
calcium transport (Kikuchi et al., 2006; Urushitani et al., 2008;
Rizzuto et al., 2012).94 Neuron 80, 80–96, October 2, 2013 ª2013 Elsevier Inc.Our observations that enhanced excitability and mTOR are
critically important to provide neuroprotection in FALS MNs are
consistent with the notion that altered calcium fluxes, e.g.,
through the ER might underlie the enhanced vulnerability of
alpha-MNs in FALS mice (Siklo´s et al., 1998; Langou et al.,
2010). Reduced ER calcium and elevated cytosolic calcium
might reduce the excitability of FALS MNs due to hyperpolar-
ization of the plasmamembrane through calcium-dependent po-
tassium currents, and inhibition of these currents might provide
one mechanism through which C-boutons protect alpha-MNs
in FALS. The larger C-boutons might augment calcium refilling
in FALS alpha-MNs (Pullen and Athanasiou, 2009), e.g., through
store-operated calcium entry involving ER membranes at
C-boutons (Shen et al., 2011), but voltage-gated calcium chan-
nel routes are also possible. Similarmechanisms relating calcium
fluxes and excitability to neurodegeneration and neuroprotection
might be relevant to other neurodegenerative diseases (Tu et al.,
2006; Palop and Mucke, 2010; Gleichmann et al., 2012). Thus,
reduced ER calcium levels and calcium gradients across the
ER as well as Calreticulin downregulation have also been related
to disease in Alzheimer’s, Parkinson’s, and Huntington’s disease
(Taguchi et al., 2000; Kipanyula et al., 2012). Furthermore, excit-
ability and synaptic calcium entry have been related to neuropro-
tective signaling (Hardingham and Bading, 2010).
In conclusion, our results provide insights into causal relation-
ships between critical early disease-related dysfunctions and
adaptive responses in FALS mice. We identify excitability
signaling and a synaptic and molecular pathway leading to
mTOR activation in alpha-MNs as critically important to provide
neuroprotection in FALS MNs. More generally, our results
provide evidence that a focus on endogenous neuroprotection
pathways in presymptomatic mice can provide valuable and
unbiased criteria to assess the potential of therapeutic strategies
in neurodegeneration.EXPERIMENTAL PROCEDURES
Mice, Reagents, and Pharmacological Treatments
B6SJL-TgN(SOD1-G93A)dl1Gur/J, referred to as slow (G93A-s), B6SJL-
Tg(SOD1-G93A)1Gur/J, referred to as fast (G93A-f), and B6SJL-Tg(SOD1-
G85R) were obtained from Jackson Laboratory. ChAT-CRE and PV-CRE
mice were from S. Arber (Biozentrum and FMI). All experiments were carried
out in male mice. Animal housing, care, and experimental procedures were
conformed to Swiss Veterinary Law guidelines.
Drug delivery regimes were based on published reports. In addition, dose-
response curves were established in FALS mice in order to avoid detectable
toxicity ranges in the mutant mice (at least one order of magnitude below toxic
dosages; see Supplemental Experimental Procedures). Drug delivery proto-
cols in all mice were as follows. Methoctramine (Sigma): injected intraperitone-
ally (i.p.) in saline at 200 mg/kg; Salubrinal (Alexis Biochemicals; dissolved at
10 mg/ml in DMSO) injected i.p. in saline at 1 mg/kg; Oxotremorine M (Tocris
Bioscience) injected i.p. in saline at 30–50 mg/kg; Rapamycin (Tocris Biosci-
ence; dissolved in ethanol at 20 mg/ml) injected i.p. in adjuvant at 6 mg/kg;
(RS)-AMPA hydrobromide (Tocris Bioscience) injected i.p. in saline (or in
sweetened drinking water, at 6 nM/l) at 15–20 nM/25 gm (or 3 nM/l in sweet-
ened drinking water for chronic treatments); CNQX at 20 mmol/l drinking water;
Tunicamycin, Brefeldin, Thapsigargin (Ascent Scientific) injected i.p. in saline
at 1 mg/g; Quizapine (Tocris) injected i.p. in saline at 0.3 mg/kg; 8OHDPAT
(Tocris) injected subcutaneously (s.c.) in saline at 0.3 mg/kg; Ketanserin
(Tocris) injected s.c. in saline at 5 mg/kg; and WAY100135 (Tocris) injected
s.c. in saline at 5 mg/kg.
Neuron
Endogenous Neuroprotection Mechanisms in ALSFor pharmacogenetic experiments, pAAV(9)-CBA-GFP-2A-floxed-
PSAM(L141F,Y115F)GlyR-WPRE at the titer of 6.3 3 1013 and pAAV(9)-
pCAG-A7-floxed-PSAM(L141F, Y115F)5HT3-WPRE at the titer of 9 3 1013
were prepared by Vector BioLabs as described (Magnus et al., 2011). A total
of 1 ml of viral suspension was injected during 30 min with a glass capillary
coupled to a Picospritzer-III apparatus in 8–10 ms pulses (Supplemental
Experimental Procedures). The ligand JFRC-PSEM-0308 (kind gift of S. Stern-
son) was administered by daily i.p. injections at the dose of 5 mg/kg in saline,
starting 5 days after viral injection.
Immunocytochemistry and Antibodies
Mice were perfused with 4% PFA in PBS, (L3–L5) lumbar spinal cord or cere-
bellum was isolated and kept overnight at 4C in 30% sucrose. After embed-
ding, 50 mmcryostat sections were post fixedwith 4%PFA for 10min, followed
by PBS washes. Antibodies (Supplemental Experimental Procedures) were
applied in PBS with 3% BSA, 0.3% Triton X-100, and incubated either over-
night or for 3 days at 4C. Sections were then briefly washed with PBS and
incubated for 120 min at room temperature with appropriate combinations
of secondary antibodies from Invitrogen.
Imaging and Image Analyses
Confocal images were acquired using a Leica SP5 (Leica Microsystems), fitted
with a 203 air objective, Olympus Fluoview (Olympus, Tokyo) microscope,
fitted with a 103 or 203 air objective, or an LSM Meta (Carl Zeiss AG) micro-
scope, fitted with a 403 oil objective. Images were processed using Imaris
software (Supplemental Experimental Procedures).
For the analysis of BiP or misf-SOD1 labeling intensities, data were acquired
using identical confocal settings, ensuring that signals at the brightest cells
were not saturated and that background levels outside MN pools were still
detectable. Images were analyzed quantitatively using Image-Pro 5 software
(Media Cybernetics). Signal intensities were measured at several regions
within areas inside cells (at least three regions per cell), excluding areas lacking
signal; average intensities were calculated and background levels outside cells
were subtracted from these values. For the calculation of MN percentages
expressing misf-SOD1, BiP, Pi-eIF2a, or p-S6, double positive MNs (MN
markers were ChAT or VAChT) and signal intensity values for the antigen of
interest were calculated over 15–20 spinal sections in triplicate animals (Sup-
plemental Experimental Procedures).SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and two figures and can be found with this article online at http://dx.doi.org/
10.1016/j.neuron.2013.07.027.
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